BlueOcean NutraSciences Inc. Announces Restart of Algae Gas Infusion Subsidiary As BlueOcean Algae Inc.
February 16, 2017 (Source) — BlueOcean NutraSciences Inc. (TSXV:BOC; FRA:4O21) (“BlueOcean” or the “Company”) is pleased to announce that it will restart its dormant algae gas infusion subsidiary targeting commercial Omega-3 and astaxanthin based algae companies utilizing minimal capital or resources. Their algae wellness products perfectly complement the Company’s astaxanthin and Omega-3 rich shrimp oil wellness products. The Company’s shrimp oil derived from Newfoundland based cold water shrimp is rich in astaxanthin and Omega-3 due to these shrimp feeding on the same algae and phytoplankton. BlueOcean has partnered with John Archibald, a founder of Canzone Limited (“Canzone”) and inVentures Technologies Incorporated (“inVentures”) as well as BlueOcean. Canzone and inVentures have been commercial gas infusion companies since 2000. They have business lines in groundwater remediation, aquaculture, wellness, hydroponic, fermentation and other applications. Mr. Archibald will assess the Company’s commercial algae opportunities. The Company continues to own the perpetual rights to royalty-free use of Canzone’s gas infusion patents and inVentures’ gas infusion products upon which the Company IPO’d in 2012. These products have been proven at lab and bench scale to accelerate algae growth via dissolving and suspending fine particles of CO2 gas into water for optimal algae consumption (the “Technology”).
The Company’s algae business will operate under its subsidiary, BlueOcean Algae Inc. (“Algae Co.”). The first steps for Algae Co. will be to engage with existing commercial algae producers to test the Technology at bench scale. Upon successful test completions, Algae Co. will then look to install commercial gas infusion units to the algae companies’ existing commercial algae operations on a royalty or incremental yield sharing model.
The Technology was proven to accelerate algae growth in 2009-2011 at lab and bench scale at the National Research Council of Canada’s Algae Labs in Sandy’s Cove Nova Scotia, which showed incremental algae yields of up to 300% when grown in CO2 gas dissolved and infused water versus baseline traditional micro-bubbling of CO2 gas.
“BlueOcean’s origin was to service emerging algae companies by accelerating their algae growth rates thereby lowering their fixed and variable costs. With Gavin and his team having now commercialized our astaxanthin and Omega-3 rich shrimp oil products, we will now give fresh attention to primarily successful astaxanthin and Omega-3 algae companies. The selected revival of the algae business will require minimal capital or resources” said John Archibald.
BlueOceanNutraSciences Inc. is a Canadian listed public Company that is focused on developing sustainable, specialty nutraceutical products targeted at the rapidly growing natural health products markets, with a current focus on the $4B Omega-3 heart health supplement market, the $9B joint health market, and the $10B sports supplement market. BlueOcean’s proprietary shrimp oil ingredient contains high levels of naturally occurring astaxanthin, phospholipids, and omega-3 EPA and DHA, enabling the product to be targeted across all three markets described above.
Get our daily investorintel update
BlueOcean’s consumer brand, Pure Polar(R) Omega-3 Shrimp Oil, contains over two times more omega-3 EPA & DHA and 10 times more astaxanthin than typicalretail krill oil brands, and contains phospholipids for better absorption of the essential nutrients. Pure Polar(R)may be purchased at the following on-line stores:
This news release may contain forward-looking statements that are based on BlueOcean’s expectations, estimates and projections regarding its business and the economic environment in which it operates. These statements are not guarantees of future performance and involve risks and uncertainties that are difficult to control or predict. Therefore, actual outcomes and results may differ materially from those expressed in these forward-looking statements and readers should not place undue reliance on such statements. Statements speak only as of the date on which they are made, and the Company undertakes no obligation to update them publicly to reflect new information or the occurrence of future events or circumstances, unless otherwise required to do so by law.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
InvestorIntel is a trusted source of reliable information at the forefront of emerging markets that brings investment opportunities to discerning investors.